Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

Sebastian Giebel, Anna Czyz, Iwona Hus, Lidia Gil, Krzysztof Giannopoulos, Joanna Romejko-Jarosinska, Maciej Majcherek, Agnieszka Szeremet, Anna Wache, Paulina Kwasnik, Wlodzimierz Mendrek, Wojciech Jurczak

Blood (2024) 144 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2024-209931

Published: 2024

Journal Articles

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Blood (2024) 144 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2024-201076

Published: 2024

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Blood (2023) 142 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2023-189537

Published: 2023

Journal Articles

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2023) 142 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2023-186517

Published: 2023

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, Matthew McKinney, Dariusz Woszczyk, Krzysztof Giannopoulos, Wojciech Jurczak, Diana Dunshee, Annie Yang, Mingzhu Zhou, Naseer Qayum, Gila Sellam, Netanel A. Horowitz

Blood (2022) 140 (Supplement 1): 1778–1780.

https://doi.org/10.1182/blood-2022-157768

Published: 2022

Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Blood (2021) 138 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2021-147460

Published: 2021

Journal Articles

The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies

Chan Yoon Cheah, Wojciech Jurczak, Masa Lasica, Tomasz Wróbel, Stanley Cheung, Jan Walewski, Krzysztof Giannopoulos, Costas K. Yannakou, Katharine L Lewis, Monika Dlugosz-Danecka, Hari P. Miskin, Alejandro D. Ricart, Owen A. O'Connor, Constantine S. Tam

Blood (2021) 138 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2021-145911

Published: 2021

Journal Articles

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood (2021) 138 (Supplement 1): 396.

https://doi.org/10.1182/blood-2021-148457

Published: 2021

Journal Articles

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Andreas Agathangelidis, Anastasia Chatzidimitriou, Katerina Gemenetzi, Veronique Giudicelli, Maria Karypidou, Karla Plevova, Zadie Davis, Xiao-Jie Yan, Sabine Jeromin, Christof Schneider, Lone Bredo Pedersen, Renee C. Tschumper, Lesley-Ann Sutton, Panagiotis Baliakas, Lydia Scarfò, Ellen J. van Gastel, Marine Armand, Eugen Tausch, Bella Biderman, Constance Baer, Davide Bagnara, Alba Navarro, Anne Langlois de Septenville, Valentina Guido, Gerlinde Mitterbauer-Hohendanner, Aleksandar Dimovski, Christian Brieghel, Sarah Lawless, Manja Meggendorfer, Kamila Brazdilova, Matthias Ritgen, Monica Facco, Cristina Tresoldi, Andrea Visentin, Andrea Patriarca, Mark Catherwood, Lisa Bonello, Andrey Sudarikov, Katrina Vanura, Maria Roumelioti, Hana Skuhrova Francova, Theodoros Moysiadis, Silvio Veronese, Krzysztof Giannopoulos, Larry Mansouri, Teodora Karan-Djurasevic, Raphael Sandaltzopoulos, Csaba Bödör, Franco Fais, Arnon Kater, Irina Panovska, Davide Rossi, Salem Alshemmari, Panagiotis Panagiotidis, Paul Costeas, Blanca Espinet, Darko Antic, Letizia Foroni, Marco Montillo, Livio Trentin, Niki Stavroyianni, Gianluca Gaidano, Paola Francia di Celle, Carsten Niemann, Elias Campo, Achilles Anagnostopoulos, Christiane Pott, Kirsten Fischer, Michael Hallek, David Oscier, Stephan Stilgenbauer, Claudia Haferlach, Diane Jelinek, Nicholas Chiorazzi, Sarka Pospisilova, Marie-Paule Lefranc, Sofia Kossida, Anton W. Langerak, Chrysoula Belessi, Frederic Davi, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 137 (10): 1365–1376.

https://doi.org/10.1182/blood.2020007039

Published: 2021

Includes: Supplemental data

Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Blood (2020) 136 (Supplement 1): 37–39.

https://doi.org/10.1182/blood-2020-134783

Published: 2020

Journal Articles

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

Krzysztof Jamroziak, Krzysztof Giannopoulos, Tomasz Wrobel, MD PhD, Adam Nowicki, Bartosz Pula, Norbert Grząśko, Justyna Rybka, Paweł J. Robak, MD, Agnieszka Druzd-Sitek, Adam Walter-Croneck, Katarzyna Brzeźniakiewicz-Janus, MDPhD, Jarosław Czyż, Krzysztof Warzocha, Dominik Dytfeld

Blood (2017) 130 (Supplement 1): 5404.

https://doi.org/10.1182/blood.V130.Suppl_1.5404.5404

Published: 2017

Journal Articles

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies

Blood (2017) 130 (14): 1628–1638.

https://doi.org/10.1182/blood-2016-08-736066

Published: 2017

Includes: Supplemental data

Journal Articles

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Malgorzata Zajac, PhD, Joanna Zaleska, Anna Dolnik, PhD, Anna Siwiec, PhD, Olga Jankowska-Lecka, PhD, Radoslaw Mlak, PhD, Marzanna Ciesielka, PhD, Tomasz Gromek, MD PhD, Bozena Sokolowska, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Maria Majdan, MD, Marek Hus, MD PhD, Lars Bullinger, MD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 1685.

https://doi.org/10.1182/blood.V128.22.1685.1685

Published: 2016

Journal Articles

Detailed Clinical, Immunological and Molecular Analysis of NOTCH1 , SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals

Maciej Putowski, Marta Podgórniak, Marta Piróg, Joanna Knap, Jacek Zawislak, Joanna Zaleska, Ewelina Zakrzewska, PhD, Joanna Purkot, Agnieszka Karczmarczyk, PhD, Paulina Wlasiuk, PhD, Waldemar Tomczak, MD PhD, Edyta Cichocka, MD PhD, Edyta Subocz, MD, Janusz Halka, MD PhD, Daria Zawirska, MD PhD, Witold Jeleniewicz, Andrzej Stepulak, MD PhD, Tomasz Stoklosa, MD PhD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 5570.

https://doi.org/10.1182/blood.V128.22.5570.5570

Published: 2016

Journal Articles

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Grazyna Stasiak, PhD, Malgorzata Zajac, PhD, Joanna Zaleska, Michal Kielbus, PhD, Jakub Czapinski, Andrzej Stepulak, MD PhD, Olga Jankowska-Lecka, PhD, Tomasz Gromek, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Bozena Sokolowska, MD PhD, Marek Hus, MD PhD, Lars Bullinger, MD PhD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 2878.

https://doi.org/10.1182/blood.V128.22.2878.2878

Published: 2016

Journal Articles

Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites

Andreas Agathangelidis, Anastasia Hadzidimitriou, Eva Minga, Lesley-Ann Sutton, Eleftheria Polychronidou, Tait D. Shanafelt, MD, Zadie Davis, Xiao-Jie Yan, MD PhD, Karla Plevova, Myriam Boudjoghra, Alba Navarro, Davide Rossi, Lone Bredo Pedersen, Vasilis Bikos, Panagiotis Baliakas, Lydia Scarfò, MD, Mattias Mattsson, Aliki Xochelli, MD PhD, Paola Francia di Celle, Krzysztof Giannopoulos, Katrina Vanura, Ludo Evers, Silvio Veronese, Monica Facco, Panagiotis Moschonas, Vojtech Bystry, Teodora Karan-Djurasevic, Maria Roumelioti, Sonja Pavlovic, Larry Mansouri, Charles Chu, Evangelia Stalika, Veronique Giudicelli, Panagiotis Panagiotidis, Andrey Sudarikov, Achilles Anagnostopoulos, Livio Trentin, MD, Mark Catherwood, Marco Montillo, MD, Niki Stavroyianni, MD, Gianluca Gaidano, Elias Campo, Carsten Utoft Niemann, Anton W. Langerak, Sarka Pospisilova, Marie-Paule Lefranc, Ulrich Jaeger, Arnon Kater, MD PhD, Christiane Pott, Nicholas Chiorazzi, MD, David Oscier, Diane F. Jelinek, Stephan Stilgenbauer, Michael Hallek, Dimitrios Tzovaras, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos, MD PhD

Blood (2016) 128 (22): 4376.

https://doi.org/10.1182/blood.V128.22.4376.4376

Published: 2016

Journal Articles

Imatinib Generics in Treatment of Chronic Myeloid Leukemia; A Prospective Observation in Large Cohort of Patients from Polish (PALG) Imatinib Generics Registry

Tomasz Sacha, Joanna Gora-Tybor, Monika Szarejko, MD PhD, Grażyna Bober, MD, Olga Grzybowska-Izydorczyk, Joanna Niesiobędzka-Krężel, MD, Marek Dudziński, MD, Ewa Wasilewska, MD PhD, Krzysztof Myśliwiec, MD, Justyna Gil, MD PhD, Michał Gniot, MD PhD, Iwona Pietkun, MD, Ewa Mędraś, MD PhD, Joanna Wącław, MD, Krzysztof Giannopoulos

Blood (2016) 128 (22): 629.

https://doi.org/10.1182/blood.V128.22.629.629

Published: 2016

NARROW

Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Detailed Clinical, Immunological and Molecular Analysis of NOTCH1 , SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites

Imatinib Generics in Treatment of Chronic Myeloid Leukemia; A Prospective Observation in Large Cohort of Patients from Polish (PALG) Imatinib Generics Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only